Protein Glutathionylation in the Regulation of Peroxiredoxins: A Family of Thiol-Specific Peroxidases That Function As Antioxidants, Molecular Chaperones, and Signal Modulators

Ho Zoon Chae,^{1,*} Hammou Oubrahim,^{2,*} Ji Won Park,³ Sue Goo Rhee,⁴ and P. Boon Chock²

Abstract

Significance: Reversible protein glutathionylation plays an important role in cellular regulation, signaling transduction, and antioxidant defense. This redox-sensitive mechanism is involved in regulating the functions of peroxiredoxins (Prxs), a family of ubiquitously expressed thiol-specific peroxidase enzymes. Glutathionylation of certain Prxs at their active-site cysteines not only provides reducing equivalents to support their peroxidase activity but also protects Prxs from irreversible hyperoxidation. Typical 2-Cys Prx also functions as a molecular chaperone when it exists as a decamer and/or higher molecular weight complexes. The hyperoxidized sulfinic derivative of 2-Cys Prx is reactivated by sulfiredoxin (Srx). In this review, the roles of glutathionylation in the regulation of Prxs are discussed with respect to their molecular structure and functions as antioxidants, molecular chaperones, and signal modulators. **Recent Advances:** Recent findings reveal that glutathionylation regulates the quaternary structure of Prx. Glutathionylation of Prx I at Cys⁸³ converts the decameric Prx to its dimers with the loss of chaperone activity. The findings that dimer/oligomer structure specific Prx I binding proteins, *e.g.*, phosphatase and tensin homolog (PTEN) and mammalian Ste20-like kinase-1 (MST1), regulate cell cycle and apoptosis, respectively, suggest a possible link between glutathionylation and those signaling pathways. **Critical Issues:** Knowing how glutathionylation affects the interaction between Prx I and its nearly 20 known interacting proteins, *e.g.*, PTEN and MST1 kinase, would reveal new insights on the physiological functions of Prx. **Future Directions:** *In vitro* studies reveal that Prx oligomerization is linked to its functional changes. However, *in vivo* dynamics, including the effect by glutathionylation, and its physiological significance remain to be investigated. *Antioxid. Redox Signal.* 16, 506–523.

Introduction

THE ACTIVITIES OF MANY KEY ENZYMES and regulatory proteins in cell signaling pathways and in cellular metabolism are regulated by reversible covalent modifications. These post-translational modification reactions are catalyzed by converter enzymes; for example, protein kinase and phosphatase catalyze phosphorylation and dephosphorylation reactions, respectively, and thioltransferase/glutaredoxin (Grx) catalyzes glutathionylation/deglutathionylation reactions (20, 102, 119). These signaling pathways involve the action of one enzyme upon another to constitute a cyclic cascade system, which has been shown to possess enormous capacity for integrating biological information and for signal

and rate amplification (19, 51, 124). Cyclic cascades involving reversible protein glutathionylation are mediated by redox signals that are produced, at least in part, in response to agonist binding to various cell surface receptors (4, 5, 102, 125). The physiological importance of this regulatory mechanism is substantiated by glutathione (GSH), the donor molecule, being a major redox buffer maintaining a reduced state of protein thiols in cells and being present in the millimolar concentration range in most cell types (39, 52). Several *in vitro* investigations revealed that protein glutathionylation leads to functional changes in nearly 100 proteins (27, 71, 79, 102). However, only a few studies have revealed glutathionylation-dependent changes in enzyme-specific activity or protein cytoskeletal function in a physiological context (79). They

¹School of Biological Sciences and Technology, Chonnam National University, Gwangju, Korea.

²Laboratory of Biochemistry, Biochemistry and Biophysics Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

³Molecular Medicine Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.

⁴Division of Life and Pharmaceutical Sciences, Ewha Womans University, Seoul, Korea.

*These authors contributed equally to this article.

include studies on the protein tyrosine phosphatase 1B (5, 60), ras (1), mitochondria complex II (17), glyceraldehyde-3-phosphate dehydrogenase (107), peroxiredoxin (Prx) I (89), and actin (129, 130). These findings suggest protein glutathionylation is involved in regulating a wide range of physiological processes. Furthermore, protein glutathionylation can also protect the protein thiol moiety from being hyperoxidized to its irreversible sulfinic acid derivative. The regeneration of the deglutathionylated protein is catalyzed by Grx. Thus, reversible protein glutathionylation has emerged as a major cellular regulatory mechanism in cell signaling and metabolism, as well as a major antioxidant defense to counter oxidative insults.

Free radicals and reactive oxygen species (ROS) play a major role in normal biological functions. They include the bactericidal action of neutrophils and macrophages, cellular signal transduction, and activation of transcriptional factors, and they are formed as intermediates in many enzyme-catalyzed reactions. However, they can also react rapidly with biomacromolecules such as nucleic acids, lipids, and proteins and lead to the loss/change of their biological functions. Therefore, they have been associated with the etiology and/or progression of a number of diseases and with aging (for reviews, see [6, 101, 123, 127]). Free radicals and ROS are formed as unavoidable byproducts of normal electron transport processes and as products of reactions between metabolites, such as hydrogen peroxide or alkyl peroxides and trace amounts of iron or copper. Thus, it is necessary for a functionally healthy cell to maintain an elegant regulatory mechanism to prevent the accumulation of harmful concentrations of ROS yet allow the accumulation of ROS to mediate their diverse physiological functions. To this end, cells rely on several enzymes including peroxiredoxins (Prxs), a family of ubiquitously expressed heme- and selenium-free thiol-specific peroxidases. These enzymes possess multiple functions in stress protection as antioxidants, molecular chaperones, and regulators of signal transduction. Prxs appear to play a role in maintaining a transient and cellular location specific environment with an elevated level of ROS for signaling activation of cascades, as well as in eliminating ROS from inducing cytotoxicity.

Prxs, found in all kingdoms with multiple isoforms, are among the most abundant proteins in most cells. This family of antioxidants was initially identified, purified, and characterized as "protector" proteins in *Saccharomyces cerevisiae* (62, 63). Without knowing its function, one member of this family, "torin," was isolated from red blood cells early on and later identified as Prx II (46). The correct annotation for the first time was "thioredoxin peroxidase"—reducing peroxides with the use of thioredoxin (Trx) (9), and later "peroxiredoxin"—reflecting an expansion of family members using other than Trx as an electron donor such as GSH, trypanedoxin, and the 57-kDa component of alkylhydroperoxide reductase (AhpF) (12, 53, 85, 103). Prxs are not confined to cytosol. They are also found in mitochondria, chloroplasts, nuclei, peroxisomes, and extracellular regions (28, 40, 41, 69, 103, 105, 121, 126, 136). This family of peroxidases exerts their antioxidant function by reducing H_2O_2 , organic hydroperoxides and peroxynitrite using intracellular reducing equivalents containing thiol (48, 104). Based on sequence and structural homology, Prxs have been proposed to comprise six subfamilies, namely, Prx A, B, C, D, E, and F (29). However, another classification, based on

the structure, number, and location of conserved Cys residues and their contribution to peroxidase catalysis, is more commonly accepted and is preferentially applied to mammalian Prxs. In this classification, Prxs are grouped into three subfamilies (typical 2-Cys, atypical 2-Cys, and 1-Cys) (Fig. 1) (103, 105, 136). Mammalian cells express six Prx isoforms (Prx I–VI), but all isoforms are not necessarily expressed in one cell at the same time. The typical 2-Cys Prx subfamily consists of Prx I–IV. These four 2-Cys Prxs share >70% amino acid sequence identity (103), and they possess both conserved N- and C-terminal Cys residues. The conserved N-terminal low pKa Cys is referred to as the peroxidatic Cys (S_P) while the conserved cysteine residue at the C-terminal region is the resolving cysteine (S_R). Most Prx proteins with the S_P in reduced state form a head-to-tail homodimer, which in turn serves as a building block for a doughnut-shaped decamer, composed of five homodimer pairs (Fig. 2) (115, 134). During peroxidase catalysis, the peroxidatic Cys is oxidized by either H_2O_2 , organic peroxide (ROOH), or peroxynitrite ($ONOO^-$) to form a sulfenic acid derivative (S_P-OH) with a second order rate constant in the range of 10^5 to $10^7 M^{-1} s^{-1}$ at pH 7.4 (36, 87). This unusually rapid oxidation is attributed to the hydrogen-bonding network created by the four conserved amino acid residues (Pro, Thr, Arg, and Glu/Gln/His) present in all Prx active sites, which stabilize the S_P thiolate anion and activate the peroxide substrate (44) (Fig. 3). The sulfenic derivative, (S_P-OH), in turn forms an intermolecular disulfide bond with the conserved resolving Cys (S_R) of another polypeptide in the dimer (see Fig. 2A). The intermolecular disulfide formation requires local unfolding because the distance between the S_P and S_R is $\sim 13 \text{ \AA}$, too far apart for disulfide bond formation (134). The latter effect weakens the dimer–dimer interaction, resulting in the dissociation of the decamer to five dimers. The S_P-S_R disulfide bond is reduced specifically by a Trx system (Trx/TrxR/NADPH) composed of Trx, thioredoxin reductase (TrxR), and NADPH (9–11, 56). In contrast, atypical 2-Cys Prx exhibits about 20% sequence identity with the four typical 2-Cys Prx isoforms. The atypical 2-Cys Prx (Prx V) contains only the conserved peroxidatic Cys (S_P) residue at its N-terminal region. However, its peroxidase activity requires the participation of one additional, nonconserved Cys residue in the same polypeptide. During catalysis, the sulfenic acid derivative formed at the peroxidatic cysteine in the atypical 2-Cys Prx reacts with a resolving cysteine residue to form an intramolecular disulfide bond (Fig. 4) (31). This intramolecular disulfide bond is then reduced either by a cytosolic or a mitochondrial Trx system (65, 118). It should be pointed out, however, that the atypical 2-Cys Prx from poplar accepts both Trx and Grx (67, 110), while the atypical 2-Cys Prx from yeast (Ahp1p) is reduced only by Trx (67). In the case of the 1-Cys Prx (Prx VI), it also contains one conserved Cys residue at the N-terminal region, required for its peroxidase activity (103–105, 136). However, Prx VI does not possess a second cysteine residue for disulfide bond formation; therefore, its resolving mechanism is more complex. The sulfenic acid intermediate formed following its reaction with H_2O_2 or ROOH has been shown to be reduced by nonphysiological thiols such as dithiothreitol (DTT) but not by Trx or Grx (61). It has also been reported that the physiological reductant could be the GSH in conjunction with the π isoform of glutathione S-transferase in the case of mammalian 1-Cys Prx (PrxVI) (34, 75, 100) (to be discussed later). However, TrxR, Grx, and ascorbate have

FIG. 1. Peroxidase catalytic mechanisms of peroxidoxin (Prx). All of the subfamily members of Prx are obligatory dimers. Typical 2-Cys subfamily members form two intermolecular disulfide bonds by resolving the sulfenic derivative (Cys-SOH) of peroxidatic Cys. Atypical 2-Cys Prx forms one intramolecular disulfide bond per each monomer, despite the fact that it exists in an antiparalleled dimer like typical 2-Cys Prx. Whereas, 1-Cys Prx does not form a disulfide due to an unavailability of proximal Cys residue for resolving. Glutathione with π isoform of glutathione *S*-transferase (π -GST) is required for the resolution of peroxidatic Cys-OH.

been reported to serve as reductants for yeast mitochondrial 1-Cys Prx (42, 81, 94).

During the reduction of H₂O₂ or ROOH, the oxidation of the peroxidatic cysteine in Prxs may not stop at its sulfenic acid state. When the sulfenic intermediate is further oxidized to form a sulfinic acid (Cys-SO₂H) derivative, or oxidized to an irreversible sulfonic acid (Cys-SO₃H) derivative, Prx loses its peroxidase activity (98, 138). However, in the case of the typical 2-Cys Prxs, their sulfenic derivatives can be reduced to sulfenic acid, catalyzed by the sulfiredoxin (Srx), conserved

only among eukaryotes, in the presence of MgATP (7, 131, 132) (Fig. 5). This unique Srx-mediated reactivation of the inactive sulfenic derivative of Prx in eukaryotes would constitute a mechanism for cells to accumulate sufficient quantities of H₂O₂ to induce signal transduction at a specific cellular location in a time-dependent manner. This notion is sometimes referred to as a floodgate hypothesis (102, 135). In addition, when typical 2-Cys Prxs are hyperoxidized, they form higher-order oligomeric structures. These high molecular weight complexes have been shown to gain a molecular

FIG. 2. Quaternary structure of Prxs. (A) Dimeric structure of rat isoform of human Prx I with the disulfide bond between S_p and S_R (ball and stick with sulfur atom colored yellow). This figure is based on a figure from Hirotsu *et al.* (47). (B) Decameric structure of human Prx I adopted from a figure from Schroder *et al.* (115). (To see this illustration in color the reader is referred to the web version of this article at www.liebertonline.com/ars).

FIG. 3. Schematic representation of the active site of H_2O_2 -bound Prx. Hydrogen bonding, involving both the protein backbone and side-chain atoms of the conserved four amino acid residues (Pro, Thr, Arg, and Glu/Gln/His) stabilizes the thiolate anion of the peroxidatic cysteine (C_P) and activates the H_2O_2 molecule for the nucleophilic attack by the thiolate anion. For the Prx-bound H_2O_2 molecule, the oxygen atoms O_A and O_B represent the electrophilic center and the atom to be displaced, respectively. This figure is based on a figure from Hall *et al.* (45).

chaperone activity (55, 72). The chaperone activity is capable of protecting protein substrates from thermally induced aggregation, resembling the heat shock proteins that also form well-ordered oligomers. Thus, the cellular protective effect of Prx is not limited to the removal of H_2O_2 or ROOH; it also directly protects proteins from irreversible denaturation.

Protein Glutathionylation of 2-Cys Prxs

Using proteomic analysis, Prx I in human T lymphocytes and atypical 2-Cys Prx, Prx V, in rat hepatocytes and human hepatoma cells were found to undergo glutathionylation when the cells were treated with a millimolar concentration range of H_2O_2 or with 1 mM of diamide, which generated a significantly higher level of glutathionylated proteins (37, 38). However, since diamide, a strong oxidant that promotes mixed disulfide formation with thiols, such as GSH, that would not occur under natural conditions (66), the Prx glutathionylation induced by diamide may not be physiologically relevant. Recently, it was reported that Prx I was glutathionylated in A549 (human lung carcinoma) and HeLa cells after treatment with micromolar concentration of H_2O_2 (88). To identify the potential glutathionylation sites, purified recombinant human Prx I or its C83S/C173S, C52S/C173S, and C173S/C83S mutants were treated with GSSG in Tris buffer at pH 7.4 and incubated for 18 h at 4°C . The glutathionylated Prx I products were analyzed using reverse phase high-pressure liquid chromatography coupled with an electrospray mass spectrometric method. These *in vitro* studies revealed that among the four cysteine residues found in Prx I, three of them, including the peroxidatic (Cys^{52}) and the resolving (Cys^{173}) cysteine, and Cys^{83} were found glutathionylated. Structure studies of 2-Cys Prxs have revealed that the peroxidatic Cys is located $\sim 14 \text{ \AA}$ apart from the resolving Cys

FIG. 4. Ribbon diagram of a monomer of human Prx V. This structure shows a possible conformation forming an intramolecular disulfide bond between the C_P (Cys^{47}) and Cys^{151} . This figure is based on a figure from Evrard *et al.* (31). (To see this illustration in color the reader is referred to the web version of this article at www.liebertonline.com/ars).

in the homodimer of Prx and that Cys^{83} is located at the dimer-dimer interface (47, 115). The potential physiological function of Cys^{83} glutathionylation is discussed below. Glutathionylated Prxs have also been observed as reaction intermediates in the catalytic mechanism of peroxidase activity of human 1-Cys Prx VI (75), 2-Cys Prxs from *Schistosoma mansoni* (113), poplar Prx, a homolog of mammalian Prx V (30, 92, 109), as well as rice Grx (OsGrx) (68).

De glutathionylation of protein-GSH mixed disulfides (protein-SSG) is known to be efficiently catalyzed by the thio-disulfide oxidoreductase, Grx. The catalytic action of Grx accounts for most of the de glutathionylating activity observed in mammalian cells (23, 59). Among the Grx isozymes, the mammalian cytosolic Grx I is the most thoroughly characterized de glutathionylating enzyme. It catalyzes the de glutathionylation of multiple protein substrates. However, the efficiency of Grx I-mediated de glutathionylation varies ~ 100 -fold among protein-SSG substrates studied so far (80). This suggests that substrate recognition plays an important role in cellular redox regulation. In addition to Grx I, other enzymes may also participate in catalyzing the de glutathionylation of some specific glutathionylated proteins under physiological conditions. In fact, cultured cells over-expressing human Srx have been shown to have diminished protein glutathionylation levels induced by a diazeniumdiolate, PABA/NO (33). In addition, purified recombinant Srx protein, known to catalyze the reduction of cysteine sulfinic derivative (see next section for detail), has been shown to reduce the levels of the PABA/NO/GSH-induced glutathionylated actin and protein tyrosine phosphatase 1B (PTP1B) (33). In view of the fact that protein glutathionylation is a sensitive response to the increase in H_2O_2 levels, it would not

FIG. 5. Peroxidase catalysis, hyperoxidation, and retroreduction mechanism of eukaryotic typical 2-Cys peroxiredoxin. Disulfide bond between peroxidatic and resolving Cys residues (Cys-S_P-S_R-Cys) is reduced to sulfhydryls by the use of thioredoxin (Trx). As a consequence, the distance between S_P and S_R extends to 14 Å. The sulfenic intermediate (Cys-S_P-OH) is formed by reducing H₂O₂ to water. When the H₂O₂ level is low (usually <10 μM), Cys-S_P-OH persists until approaching Cys-S_RH within the disulfide bonding radius, which requires local unfolding of the structure. When the H₂O₂ level increases, Cys-S_P-OH reacts with an additional H₂O₂ molecule to form a sulfenic intermediate (Cys-S_P-O₂⁻), consequently Prx loses its peroxidase activity until retroreduced to Cys-S_P-H. Retroreduction of Cys-S_P-O₂⁻ starts with the formation of sulfinic phosphoryl ester (Cys-(S_P=O)-OPO₃²⁻), which is catalyzed by sulfiredoxin (SrX) in the presence of ATP and Mg²⁺. The SrX-Prx thiosulfinate (Prx-Cys-(S_P=O)-S-Cys-SrX) intermediate is formed by releasing inorganic phosphate. Reduction of this thiosulfinate with glutathione (GSH) or Trx restores the hyperoxidized Prx to normal peroxidase catalytic intermediate (Cys-S_P-OH). Several reducing pathways from Cys-S_P-OH to Cys-S_P-H have been proposed involving GSH and/or Trx in the presence of SrX; however, the preference or detailed mechanism of the reaction remains to be elucidated. The dashed arrows indicate unconfirmed but possible reaction path through which GSH directly attacks the sulfinylphosphate intermediate to form Prx-(S_P=O)-SG and SrXS⁻ intermediates. The scheme shows the mechanistic pathway of one of two active sites in the dimeric structure of typical 2-Cys Prx. (To see this illustration in color the reader is referred to the web version of this article at www.liebertonline.com/ars).

be surprising that reversible glutathionylation of Prx could be involved in Prx-mediated signal transduction and physiological redox signaling because these events are associated with a specific local generation of ROS.

Role of Glutathionylation in SrX-Catalyzed Reduction of Sulfinic Acid Derivative of 2-Cys Prx

Sulfiredoxin, SrX, was discovered as an enzyme that catalyzes the reduction of the cysteine sulfinic acid derivative of typical 2-Cys Prx (7, 131). However, SrX has also been shown to exhibit glutathionyl mixed disulfide oxidoreductase activity (33, 88). Using glutathionylated Prx I as substrate, steady state kinetic analysis showed that the deglutathionylation of Cys¹⁷³ and Cys⁸³ were preferentially catalyzed by SrX, whereas Grx I was more favorable for deglutathionylating Cys⁵². Furthermore, site-directed mutagenesis at the C-terminal tail of Prx I, a potential interacting site between Prx I and SrX, coupled with binding and deglutathionylation activity studies revealed that

SrX is a specific deglutathionylating enzyme for Prx I due to its favorable affinity for the typical 2-Cys Prxs (58, 88). Mechanistic studies revealed that SrX, glutathionylated at Cys⁹⁹, is an intermediate for the deglutathionylation catalyzed by SrX (88). This more recent finding is inconsistent but more plausible than a previous report (33), which indicated that Cys⁹⁹ was not glutathionylated even though it was required for the deglutathionylation reaction. Experimental evidence in support of glutathionylated SrX as a reactive intermediate for the SrX-catalyzed deglutathionylation of Prx I includes products analysis of an on-going SrX-catalyzed deglutathionylation of the glutathionylated Prx I (C83S/C173S) mutant. The results showed the formation of the glutathionylated SrX at Cys⁹⁹ and the deglutathionylated Prx I (C83S/C173S) as well as the unreacted SrX and glutathionylated Prx I (C83S/C173S) (88). These findings are consistent with the observation that Cys⁹⁹ of SrX, exhibiting a pK_a of 7.3 (14), is easily glutathionylated and rapidly deglutathionylated by GSH (88). The physiological relevance of SrX catalyzing the deglutathionylation of

typical 2-Cys Prxs was demonstrated by the effect of Srx in regulating the level of glutathionylated Prx I induced by 10 μ M of H₂O₂ in A549 cells. The results from these experiments showed that the level of H₂O₂-induced glutathionylated Prx I was substantially elevated in small interfering RNA-mediated Srx-knocked down cells, whereas the reverse was observed in Srx-overexpressed cells. However, glutathionylation of Prx V, not known to bind to Srx, was not affected by the change in Srx expression levels (88).

The findings that Cys⁵² of Prx I and Cys⁹⁹ of Srx can easily undergo glutathionylation/deglutathionylation suggest that protein glutathionylation could be involved in the mechanism by which Srx-catalyzes the reduction of sulfinic acid derivative of typical 2-Cys Prxs (see Fig. 5). Crystallographic analysis reveals that the hyperoxidized form of 2-Cys Prx exists as a stable decameric structure with each active site buried, and its peroxidatic and resolving cysteine are located $\sim$ 14 Å apart. With this structure, the sulfinic moiety of the peroxidatic cysteine is not accessible to the active site of Srx because of the restriction imposed by the YF and GGLG motifs in Prx (115). Therefore the catalytic mechanism must involve a Srx-induced structural change in 2-Cys Prx. The X-ray crystallographic structural analysis of the Srx-Prx complex revealed that binding of ATP-Srx complex to the sulfinic derivative of Prx II indeed induces the unfolding of the Prx II active site such that its Cys⁵¹-SO₂⁻ is translocated to a position where it could readily be phosphorylated by the Srx-bound ATP to form a Prx II bound sulfinic phosphoryl ester intermediate (57). The ionized reactive Cys⁹⁹ of Srx could then interact with the phosphoryl ester intermediate to generate a thiosulfinate between Prx II and Srx and releases the inorganic phosphate (58, 111) (see Fig. 5). As shown in this mechanistic scheme, either Trx or GSH could reduce the thiosulfinate intermediate and the subsequent sulfenic acid derivative of the 2-Cys Prx I to regenerate Srx and the reduced form of Prx I. Considering the facts that (i) Srx is capable of catalyzing the deglutathionylation of glutathionylated Prx I, (ii) Srx can easily be glutathionylated and deglutathionylated at its Cys⁹⁹ (88), (iii) Trx does not reduce efficiently the oxidized Srx in the thiosulfinate intermediate, Prx-(S_p=O)-S-Srx, in the absence of Srx intramolecular disulfide formation (112), and (iv) the cellular concentration of GSH is $\sim$ 1–10 mM while Trx is in the range of 2–10 μ M (114), it is reasonable to speculate that protein glutathionylation/deglutathionylation reaction is likely involved in mediating the mechanism of Srx-catalyzed reduction of sulfinic derivative of 2-Cys-Prx in mammalian cells. It should be pointed out that with *Saccharomyces cerevisiae* Srx, Trx is the preferred cellular reductant of Srx (104) because *S. cerevisiae* Srx contains two extra cysteine residues, Cys⁴⁸ and Cys¹⁰⁶, in addition to its reactive Cys⁸⁴. The reduction of the Prx-thiosulfinate-Srx intermediate, Prx-(S_p=O)-S-Srx, is mediated by the formation of an intramolecular disulfide bond between Cys⁸⁴ and Cys⁴⁸ of Srx, which in turn is selectively reduced by Trx. Consistent with this hypothesis, when Cys⁸⁴ was mutated to alanine to prevent disulfide bond formation between Cys⁸⁴ and Cys⁴⁸ of Srx, the rate of the reduction of thiosulfinate intermediate by Trx was lower by a factor of 600. This observation excludes the thiosulfinate species as a direct target of Trx in *S. cerevisiae* (112). Because mammalian Srx contains only one cysteine, Cys⁹⁹, which precludes the formation of intramolecular disulfide bond, in addition to Trx being unable to reduce thiosulfinate favor-

ably without disulfide bond formation, a Srx-catalyzed reactivation mechanism of sulfinic acid containing 2-Cys Prx in mammals is likely to be different from that of *Saccharomyces cerevisiae*. Thus, GSH could be the reductant of choice for this catalytic process. As shown in Fig. 5, GSH could directly reduce the Prx-thiosulfinate-Srx intermediate, Prx-(S_p=O)-S-Srx, to form a glutathionylated Srx and a sulfenic derivative of Prx, which could be further reduced by GSH to form the reduced form of Prx. In addition, GSH could also directly react with the sulfinylphosphate intermediate to release P_i and form Prx-(S_p=O)-SG and SrxS⁻ as the alternative intermediates, as shown with the dashed line in Fig. 5 (74). This reactive intermediate could then rearrange in one of two ways. The Srx-S⁻ could attack the S=O or the SG of the Prx-glutathionylthiosulfinate. In the first case it would yield the Srx-thiosulfinate-Prx intermediate, while in the second case it would give the Prx-SOH, and a Prx-bound Srx-SSG as intermediates. This proposed mechanistic scheme remains to be validated.

Glutathionylation Regulates the Oligomerization and Catalytic Activities of Prx I

Structural studies reveal that 2-Cys Prxs exist in equilibrium between the head-to-tail homodimers and decamer (115, 136). Hyperoxidation of the peroxidatic cysteine would shift the equilibrium toward the formation of decamers or higher molecular weight complexes (55, 82). The structural change from lower molecular weight oligomers, including dimers, to higher molecular weight complexes is accompanied with a change of enzymic function, from peroxidase to molecular chaperone (55). On one hand, shifting the equilibrium to higher molecular weight forms need not be accompanied by the loss of their peroxidase activity, unless hyperoxidation is involved. On the other hand, the rapid and dynamic structural equilibrium that also occurs during the peroxidase catalytic assay provides a reason for a careful reevaluation of the relationship between oligomeric structure change and alteration in enzymic activity.

The effect of protein glutathionylation on the oligomeric status of Prx I has been investigated using sedimentation velocity methods and recombinant Prx I as well as its C52S/C173S and C83S mutants (89). In view of the fact that the cellular concentration of Prx I is $\sim$ 15–60 μ M (11, 89), the concentration used for the sedimentation velocity study was set mainly at 50 μ M. Under these conditions, 97% of the wild-type (WT) Prx I is present as a decamer. Concentration-dependent study revealed that the dissociation constant for the WT Prx I decamer is in the submicromolar range. However glutathionylated WT Prx I showed a different sedimentation velocity profile with a distinctly different sedimentation coefficient reflecting that glutathionylation disrupts the oligomerization of Prx I in such a way that the decameric population was totally eliminated at 50 μ M protein concentration. Instead, the glutathionylated Prx I was converted mainly to small oligomeric species, with dimers as the predominant species present in the state of dynamic equilibrium (89) (see Fig. 6). Study with yeast Prx revealed that peroxidase activity is not required for Prx to exhibit molecular chaperone activity (55). This observation is in agreement with a report showing that the reduced form of human Prx I, and Prx I (C52S/C173S), a peroxidase inactive double mutant,

FIG. 6. Protein glutathionylation of Prx I induces a decamer to dimer switch. Glutathionylation induces a structural change in Prx I and leads to the dissociation of its decamer to dimers. (To see this illustration in color the reader is referred to the web version of this article at www.liebertonline.com/ars).

exist as decamers and possess molecular chaperone activity (89). However, glutathionylation of these two Prxs led to the loss of chaperone activity and concomitantly converted the decameric structure to mainly dimers (89). It should be pointed out that the result obtained with the Prx I (C52S/C172S) mutant revealed that monogluthionylation of Prx I at Cys⁸³ is sufficient to convert the decameric enzyme, which possesses chaperone activity, to its dimeric state, which loses the molecular chaperone activity. It has been reported that Cys⁸³ is located at the putative dimer–dimer interface and it plays a role in stabilizing the hydrophobic interaction required for the decamer formation (78, 115, 136). This notion is consistent with the observation that the dissociation constant for the high molecular weight oligomer of Prx I (C83S) mutant is significantly higher than that found for WT and the (C52S/C173S) double mutant (89).

In view of the fact that glutathionylation of Cys⁸³ of Prx I is sufficient to convert the decameric Prx I to its dimeric structure (Fig. 6), the biological relevance of Cys⁸³ glutathionylation was assessed in a comparative study on glutathionylation of Prx I and Prx II in HeLa cells. Prx I and Prx II show 78% identity in their amino acid sequences and share similar peroxidase catalytic mechanism, except Prx II does not contain Cys⁸³ (103). The glutathionylation reaction was monitored using biotinylated GSH ethyl ester (BioGEE), a cell membrane permeable form of GSH, followed by cell treatment with 10–50 μ M H₂O₂. The results of this experiment revealed that glutathionylation occurred mainly on Prx I but not Prx II. This implies that Cys⁸³ in Prx I is probably easily accessible for glutathionylation with BioGEE, relative to the peroxidatic and the resolving cysteine residues in either Prx I or Prx II (89). In other words, glutathionylation of Cys⁸³ in Prx I may play a regulatory role in shifting Prx I from its decameric to dimeric form, and consequently causing a loss of its molecular chaperone activity.

When human cytosolic Prx I (cPrx I) was treated with H₂O₂, the concentration of its higher molecular weight complexes increased and its peroxidase activity correlated positively with the diminution of its low molecular weight oligomers. The dimer exhibited the highest peroxidase activity (55). In the case of molecular chaperone activity, the opposite correlation was observed. The dimer exhibited no chaperone activity while the decameric cPrx I or its higher molecular weight complexes exhibited high chaperone activity (55). However, an opposite conclusion indicating that the decamer possesses a higher peroxidase activity than that of the dimer

has been reported based on kinetic study. In this study, k_{cat} values of 55.1, 75.8, 25.0, and 31.5 s^{−1} were obtained for the reduction of H₂O₂ catalyzed by the wild-type alkyl hydroperoxide reductase (AhpC), and its T77V (favoring decamer), T77I and T77D (both favors dimer formation) mutants, respectively (91). However, the concentration of the WT AhpC used, 40–100 nM, was too low to maintain a meaningful population of decamers because the sedimentation velocity studies revealed that at 10 μ M of WT AhpC, more than 25% of the protein was present as dimer. In addition the wide variation in the value of K_m for S128W/NTD indicates that the mutation causes structural changes in AhpC and alters the kinetic properties of the mutants. Thus, the mutation does not simply change the distribution between the decamer and dimer population (91). In essence, the peroxidase activity of the reduced decamer remains to be established.

Mammalian Prx I and Prx II are mainly localized in the cytoplasm. Relative to Prx I, Prx II is a much less efficient peroxidase; however, Prx I is more susceptible to hyperoxidation and hence more readily gains chaperone activity compared with Prx II (18, 117). On the other hand, Prx I appears to have precise and versatile built-in machinery to regulate its peroxidase activity in response to local need for H₂O₂. Prx I and Prx II have been shown to associate with lipid rafts where signaling molecules such as NADPH oxidase, receptor tyrosine kinases, Src family kinases, and tyrosine phosphatases are found. Here, Prx I and Prx II would prevent the uncontrolled accumulation of H₂O₂, which in turn could activate signaling cascades. However, when cells were stimulated with growth factors, Prx I, but not Prx II, was transiently inactivated via a Src kinase-mediated tyrosine phosphorylation at Tyr¹⁹⁴ (133). This finding provides an alternative mechanism for the “floodgate hypothesis,” involving phosphorylation rather than hyperoxidation as the mean of inactivating the peroxidase activity. Although both Prx I and Prx II are associated with lipid rafts, inactivation of Prx I, which is more efficient as a peroxidase relative to Prx II, might be sufficient to allow local accumulation of H₂O₂ for signal propagation. The role of raft-associated Prx II remains to be investigated. Prx I has also been shown to be inactivated when phosphorylated at Thr⁹⁰ by cyclin B-dependent kinase 1 (Cdk1) (13). The Cdk1-catalyzed Prx I phosphorylation was observed during mitosis, but it was virtually undetectable during interphase. Consistent with this unique regulatory function of Prx I observed during growth factor stimulation and cell cycle progression, mice lacking Prx I had an increased

susceptibility to cancer, while those deficient in Prx II did not (70, 84). Prx I has also been shown to play a role in tumor suppression (8). The local accumulation of H_2O_2 is likely to cause glutathionylation at Cys⁸³ of Prx I molecules that are localized at a site where the ROS level is elevated; for example, a lipid raft during growth factor signaling. The differential susceptibility of Prx I and Prx II to phosphorylation, glutathionylation, and hyperoxidation suggests that these enzymes and modes of post-translational modification may play distinct roles in cell signaling.

What could be the functional role of Cys⁸³ glutathionylated Prx I? Kinetic studies of the reaction of peroxidatic Cys of Prx and H_2O_2 suggest that its rate constant principally depends on collision efficiency, which results from steric accessibility and reactivity of the peroxy group (36). It is reasonable to expect five active dimers remove the H_2O_2 remnant more effectively than a decamer or a higher-order oligomer. This increase in peroxidase activity would occur after a lag phase due to the glutathionylation reaction and could provide a transient accumulation of H_2O_2 to complete its signaling function prior to being efficiently removed to prevent unwanted signal transduction. Recently Morinaka *et al.* (83) reported that the oligomeric Prx I structure, induced by relatively high levels of H_2O_2 , is essential for Prx I binding and activating mammalian Ste20-like kinase-1 (MST1) kinase. Activation of MST1-kinase induces cellular apoptosis via a p53-mediated pathway. Thus, H_2O_2 appears to induce both activation and inhibition of apoptotic pathways through oligomeric structural change by hyperoxidation and via a dimeric structural change induced by glutathionylation, respectively. Considering the fact that Cys⁸³ glutathionylation is induced by a lower range of H_2O_2 relative to that capable of causing hyperoxidation, it is reasonable to speculate that Cys⁸³ glutathionylation functions as a built-in safety switch to prevent hypersusceptible initiation of the apoptotic pathway. In addition Cao *et al.* (8) revealed that Prx I inhibits tumorigenesis by binding and consequently protecting phosphatase and tensin homolog (PTEN) from oxidation-induced inactivation. Thus, Cys⁸³ glutathionylation may also function as a sensor for low levels of H_2O_2 and respond by binding to PTEN to prevent unwarranted cell growth. The structural analysis by these authors indicates that PTEN likely binds to the Prx I dimer, which could well be the glutathionylated Prx I. Together, these two reports indicate that dimer/oligomer structure specific Prx I binding proteins such as MST1 kinase and PTEN regulate apoptosis and cell cycle, respectively, suggesting a possible link of glutathionylation with those signaling pathways.

Reversible Phosphorylation, Nitrosylation and Acetylation Regulating The Catalytic Activities of Prx I and Prx II

In addition to protein glutathionylation, the catalytic activity of Prxs can be regulated by other forms of covalent modifications. For example, the peroxidase activity of Prx I and Prx II can be regulated by phosphorylation of a specific threonine or tyrosine residue (see Fig. 7). Both Prx I and Prx II are phosphorylated by cyclin-dependent kinases (Cdks) at the Thr⁹⁰ and Thr⁸⁹ of Prx I and Prx II, respectively, in a Cdk-specific phosphorylation site consensus sequence, Thr-Pro-Lys-Lys. Thr⁹⁰ of Prx I is phosphorylated by cyclin

B-dependent kinase Cdk1 and leads to the inhibition of its peroxidase activity (13). Notably the inactive Thr⁹⁰ phosphorylated Prx I, as well as the Prx I (T90D) mutant, which mimics the effect of Thr⁹⁰ phosphorylation in Prx I, exhibit significant structural changes as indicated by changes in protein surface hydrophobicity monitored by binding of bis-ANS, and by changes in tryptophan fluorescence and circular dichroism spectra. These structural changes shift the Prx I structure to higher molecular weight oligomers, which possess molecular chaperone activity (54). Although Cdk1 also phosphorylates Prx II at Thr⁸⁹, albeit at lower catalytic efficiency, Prx II has been shown to bind Cdk5/p35, which in turn phosphorylates its Thr⁸⁹ when cells were treated with 1-methyl-4-phenylpyridinium ion (MPP⁺) (97). Like Prx I, this Thr phosphorylation also leads to inhibition of Prx II peroxidase activity. Considering the crystal structure of human Prx I (47), introducing a negatively charged phosphate to Thr⁹⁰ in Prx I or Thr⁸⁹ in Prx II, which is closely located to their respective peroxidatic Cys, would affect the charge-charge or charge-dipole interaction rendering the reactive cysteine insensitive to H_2O_2 . Recently, Woo *et al.* (133) reported that Prx I is phosphorylated at Tyr¹⁹⁴ and diminishes its peroxidase activity when cells were stimulated by platelet-derived growth factor or epidermal growth factor. Contrary to the Thr and Tyr phosphorylation leading to the inhibition of peroxidase activity, Ser³² phosphorylation has been shown to enhance the peroxidase activity of Prx I (142). T-cell-originated protein kinase catalyzes the phosphorylation of Ser³², which in turn prevents UVB-induced apoptosis in RPMI7951 melanoma cells through decreasing the intracellular H_2O_2 level by an increase in peroxidase activity of Prx I (142). As mentioned earlier, Thr^{90/89} phosphorylation of Prx I/Prx II induces a structural change and leads to a switch in the enzymic activity, from peroxidase to molecular chaperone. However oligomeric structural change and activity switching were not observed in Prx I phosphorylated at Tyr¹⁹⁴ or Ser³² (133, 142). These are important observations with respect to the mechanism of cell signaling. Together, these studies reveal that the regulation and switching of the dual functions of 2-Cys Prxs appear to be mediated by post-translational modifications such as sulfinylation and phosphorylation. Both of these modifications are induced by the elevation of intracellular H_2O_2 leading to the activation or inactivation of the peroxidase activity of Prx I and II to provide a mechanism for transient depletion or accumulation of H_2O_2 which leads to downstream signaling events (43, 105, 133, 135).

Prxs have also been shown to undergo protein nitrosylation and acetylation. Protein S-nitrosylation involves covalent attachment of a NO group to a cysteine thiol and it is known to regulate the function of many target enzymes, transcription factors, and ion channels, such as Parkin (24, 139), N-methyl-D-aspartate receptors (22), protein disulfide isomerase (106), nuclear factor- κ B (77), and a number of other proteins (128, 141). Prx II has been shown to undergo S-nitrosylation by reaction with nitric oxide at its peroxidatic and resolving cysteine residues, inhibiting its peroxidase activity (32). Interestingly, these authors also found that the level of nitrosylated Prx II in the brain of patients with Parkinson's disease was elevated. Direct linkage between S-nitrosylation of Prx II and the neuronal cell death observed in Parkinson's disease remains to be established. Furthermore, Prx I has also been shown to undergo reversible N-acetylation (90, 117),

Prx I

Prx II

FIG. 7. Post-translational modifications of human Prx I and Prx II. Sulfhydryls of peroxidatic cysteine residue (C_P) of both Prx I and Prx II can be further oxidized to reversible sulfinic acid or irreversible sulfonate acid derivatives. Both forms of the hyperoxidized Prxs shift their quaternary structure equilibrium in favor of the higher-molecular weight (HMW) structures. Three Cys residues, C_P , C_R , and C83, in Prx I are the sites of glutathionylation, which is negatively regulated by glutaredoxin or Srx. Both C_P and C_R of Prx II can be S-nitrosylated by NO generated by NO synthase (NOS). N^α acetylation is found on the penultimate Ala residue of Prx II, and N-acetylation of Lys residues in Prx I at K7, K197, and K199 have been identified. Phosphorylation at T90, T183, S32, and Y194 in Prx I and at T89 in Prx II has been observed. The effects of these phosphorylations on the peroxidase activity are indicated. CDK/Cdc; EGFR, epidermal growth factor receptor; Grx, glutaredoxin; Nox, NADPH oxidase; PDGFR, platelet-derived growth factor receptor; TOPK, T-cell-originated protein kinase. (To see this illustration in color the reader is referred to the web version of this article at www.liebertonline.com/ars).

with histone deacetylase 6 catalyzing the deacetylation reaction (90). The acetylation of Prx I led to an increase in their peroxidase activity and enhanced their resistance to hyperoxidation. Investigation by Seo *et al.* (117) revealed that when hPrx I and hPrx II cDNAs were overexpressed in *Escherichia coli*, Prx I was found N-acetylated while N^α -terminal acetylation (N^α -Ac) occurred exclusively on Prx II after demethionylation at its N-terminus. While N-acetylation of Prx I has been implicated in neurodegenerative disorders (90), N^α -terminal acetylation of Prx II leads to a significant structural change and blocks Prx II from irreversible hyperoxidation without altering its peroxidase activity. It should be pointed out that N^α -terminal acetylation is regulated by the availability of acetyl CoA (140) and is generally considered an irreversible and co-translational process. The facts that (i) the stability of Prx II is protected by N^α -terminal acetylation (117), (ii) Prx II has been shown to be involved in mediating cellular apoptosis (50, 73), and (iii) metabolic regulation of protein N^α -acetylation has been reported (140) together suggest a possi-

ble linkage between N^α -terminal acetylation of Prx II and the metabolism. However, the correlations between Prx acetylation and specific cellular events remain to be elucidated.

To date, cross-talk and integrated control, as well as the hierarchy among various post-translational modifications of Prx proteins have not been identified. This could be due in part to the high intracellular concentration of Prx proteins relative to other signaling or antioxidant proteins. As a consequence, a small fraction of modified Prxs are sufficient to accomplish specific cellular needs. Therefore, single or combinatorial modifications of Prx could occur at a given time at various locations in cells. This variety of modifications may explain the wide range of intracellular functional roles of Prx proteins.

Protein Glutathionylation Provides Reducing Equivalents to Peroxidase Catalysis

The catalytic cycle for the peroxidase activity of all Prxs begins with the same oxidation of conserved peroxidatic

cysteine, S_P , to its sulfenic derivative, $S_P\text{-OH}$, by the reduction of peroxide to its corresponding alcohol. The $S_P\text{-OH}$ derivative will in turn form an intermolecular disulfide bond with the resolving cysteine, S_R , in the case of mammalian typical 2-Cys Prxs (105), an intramolecular disulfide bond in the case of mammalian atypical 2-Cys Prxs (31, 65), or a disulfide bond with GSH, Grx, or Trx in certain Prxs from plants, bacteria, or worms (29, 94, 108). Reduction of these intermediates can be accomplished by the Trx/TrxR/NADPH system, the Grx/GSH/glutathione reductase (GR)/NADPH system (49), or (Trx or GSH)/TrxGR (TGR)/NADPH system (2). In this context, *Schistosoma mansoni*, a causative agent of schistosomiasis that lacks both TrxR and GR, possesses TGR to mediate electron donors via both the Trx and the GSH systems. The three Prxs (Prx1, Prx2, and Prx3) found in *S. mansoni* are 2-Cys Prxs that use the reducing equivalents from both Trx and GSH. Among them, Prx1 shows high specificity for Trx, while Prx2 and Prx3 exhibit significantly higher catalytic efficiency with GSH as reducing agent. The GSH binding affinity is conferred by the C-terminal 22 amino acid residues (113). However, a majority of Prxs exhibiting GSH-dependent peroxidase activity are 1-Cys Prxs isolated from plants, bacteria, and pathogens. A Prx from *Haemophilus influenza* Rd (PGdx), identified as a chimeric protein composed of a Prx and a Grx in its N-terminal and C-terminal region, respectively, has been purified and characterized (92). The peroxidase activity of PGdx requires the GSH redox cycle, but not the Trx/TrxR/NADPH system. Assays with H_2O_2 as substrate yielded a k_{cat}/K_m value of $5 \times 10^6 \text{ M}^{-1} \text{ s}^{-1}$, comparable with that of the major peroxidase system of *E. coli*, AhpC (116). In addition, mass spectrometric analysis revealed that Cys^{49} of PGdx is the peroxidatic cysteine, and it was found glutathionylated in the enzyme purified from PGdx over-expressing *E. coli*. (92). Sequence analysis shows that the C-terminal region of PGdx shares strong homology with Grx 3 of *E. coli*, which has a

higher activity as reductant of glutathionylated proteins than *E. coli* Grx 1 and 2 (3). This Grx-homologous domain contains the CXXC motif of Grx at cysteine residues 180 and 183. Interestingly, Grx has also been shown to function, like Trx, as an electron donor to reduce the sulfenic derivative of an oxidized poplar phloem Prx (109). Based on protein analysis showing Cys^{49} can be glutathionylated and the kinetic study displaying a sigmoidal kinetics as a function of increasing the concentration of GSH, a catalytic mechanism for the peroxidase activity of PGdx was proposed with glutathionylated Cys^{49} and Cys^{180} as reaction intermediates (92) (see Fig. 8). In this mechanism, the sulfenic acid formed at Cys^{49} reacts with GSH to form a glutathionylated PGdx at its N-terminal Prx region. Reaction 3 shows the deglutathionylation of the Prx region by Cys^{180} of the C-terminal Grx region. This Cys^{180} glutathionylated intermediate is in equilibrium with the formation of a disulfide bridge between Cys^{180} and Cys^{183} at the active site of the Grx region as shown in reaction 6. This is an unproductive side reaction. Altogether this mechanism indicates that at a low GSH concentration, only a relatively small fraction of the total enzyme population remains reduced and active. However, when the concentration of GSH is increased until reaction 6 becomes insignificant, the Grx region would be fully active. This proposed mechanism could explain the observed sigmoidal kinetics and is consistent with data showing the sigmoidicity was not detected with a Cys^{183} mutant of PGdx (92).

Protein Glutathionylation of 1-Cys Prx and Its Peroxidase Catalytic Cycle

Peroxiredoxin VI was first isolated as a nonselenium GSH peroxidase purified from the bovine ciliary body. It catalyzes the reduction of both H_2O_2 and organic hydroperoxides using GSH and yet does not have any GSH S-transferase (GST)

FIG. 8. A mechanistic scheme depicting the reduction of ROOH catalyzed by PGdx is mediated by the GSH redox cycle. PGdx is a chimeric enzyme from *Haemophilus influenza* Rd which consists of the N-terminal peroxiredoxin (light section) and the C-terminal glutaredoxin (gray section) region. The reaction steps 1 to 5 were proposed by Pauwels *et al.* (92) to explain their observed data, while the steps represented by the dotted lines were proposed by Rouhier *et al.* (109) for the Grx-reducible poplar Prx and adopted here.

activity (120). A 28-kDa protein was purified from rat olfactory epithelium whose N-terminal sequencing showed that it has a high homology with the nonselenium GSH peroxidase previously purified from bovine ciliary body. Furthermore, their substrate specificity and enzymic activity are comparable (95). cDNA identification and the deduced protein sequence confirmed that this protein belongs to the Prx family (Prx/Prdx). The Prx VI isolated from rat and bovine contains only the single conserved Cys⁴⁷. However, unlike the rat and bovine Prx VI that possess only one cysteine residue, an additional nonconserved Cys is found in human (C91) and mouse (C201) proteins. In human Prx VI, Cys⁹¹ can be substituted by serine without affecting the peroxidase activity (61). Like the other Prxs, Prx VI contains a typical Trx fold with ~80 amino acids arranged in four antiparallel β sheets sandwiched between two α helices (21). This region is essential for the peroxidative function of the enzyme. Furthermore, the sequence surrounding the peroxidatic cysteine in Prx VI and typical 2-Cys Prx I to IV are very similar, PVCTTE and FVCPTE, respectively. However, despite Prx VI sharing the structural and functional properties with other members of the Prx family, it has important characteristics that make it unique among the Prx family members. First, unlike both typical (Prx I to IV) and atypical (Prx V) 2-Cys Prx family members, Prx VI has only one conserved cysteine located at the N-terminal region (Cys⁴⁷) involved in the peroxidase activity (136). In addition, the oxidation of peroxidatic cysteine (Cys⁴⁷) to Cys⁴⁷-SOH in Prx VI does not form a disulfide bond despite the fact that the enzyme forms a homodimer via its C-terminal domain involving probably hydrophobic interaction (21). A crystal structure study revealed that in the oxidatively inactivated Prx VI homodimer, the cysteine in each monomer exists as cysteine-sulfenic acid, positioned far apart from others and located in the bottom of a relatively narrow pocket. Generally, sulfenic acids are unstable and highly reactive (25, 26). However, it was found that cysteine sulfenic acid was quite stable in native Prx VI even under aerobic conditions. Further oxidation of the cysteine sulfenic acid of bovine Prx VI to higher oxidation states was observed only under denaturing conditions (96). Transformation of sulfenic acids proceeds through thiosulfinate formation by the self-condensation reaction of two RSOHs or oxidation to sulfinic acid. Sulfenic acids can also react with R-SH and R-NH₂ to give disulfides and sulfenamides, respectively (25, 26). However the distance between the cysteine residues in the oxidatively inactivated dimer form and their location do not allow Prx VI to dimerize through disulfide bond formation in the native form. Instead, Prx VI, which exists as an obligatory dimer, forms a homodimer through hydrophobic interaction. A distinctive property of Prx VI from other Prxs is that Trx is not involved in the catalytic cycle (35, 61). Nevertheless, it is worth noting that this is not a general rule that can be applied to all 1-Cys Prx. For example, Prx1p, a 1-CysPrx of budding yeast *Saccharomyces cerevisiae* is located in the mitochondria, and it is induced when the cellular respiratory pathway is in operation, as well as when yeast is responding to oxidative stress. Contrary to human Prx VI, yeast Prx1p showed peroxidase activity *in vitro* using the *S. cerevisiae* mitochondrial Trx system as electron donor (93).

The role of GSH in the catalytic cycle of Prx VI has been controversial for some time. The peroxidase protein purified

from bovine ciliary body was shown to be dependent on GSH (120). Later on, translated protein *in vitro* with a bovine cDNA was also found to utilize GSH as a reductant for the peroxidase activity (122). In contrast to the previous study using the protein from *in vitro* translation system, an *in vitro* assay with the recombinant human or bovine protein indicated that GSH was not an effective reductant (61, 95). The controversy surrounding the role of GSH in the Prx VI catalytic cycle was recently put to rest, and the further detailed catalytic cycle is summarized in following text and depicted in Fig. 9. It has been shown that the partial purification of Prx VI from bovine lung revealed the presence of the π isozyme of GST (π GST) in active preparations. Additional experiments showed that the heterodimerization of Prx VI and π GST led to the glutathionylation of the cysteine sulfenic acid followed by the spontaneous reduction of the mixed disulfide leading to the restoration of the peroxidative activity of the enzyme (75). These results were later elegantly confirmed by a study showing that purified recombinant human Prx VI is able to form a complex with GSH-loaded π GST leading to its full activation (99). Interestingly, Prx VI can form a complex with π GST even in the presence of S-methylglutathione showing that the heterodimer formation does not require the reducing power of GSH. Under these conditions, the protein has no peroxidase activity. However, the yield of the heterodimer is very low in the absence of GSH suggesting that GSH binding to π GST induced a conformational change that favors the heterodimer formation between π GST and Prx VI. In addition, this Prx VI homodimer does not have any peroxidase activity even in the presence of GSH, showing that GSH alone cannot activate the inactive form of Prx VI. This result suggests that the heterodimerization with π GST, a GSH carrier, is a key step in overcoming the inaccessibility of oxidized cysteine residue in inactive human Prx VI (see Fig. 9). Immediately after the heterodimer formation, Prx VI is glutathionylated at the peroxidatic cysteine residue, but the enzyme is still inactive. This step is followed by the disulfide bond formation between glutathionylated Cys⁴⁷ of Prx VI and Cys⁴⁷ of π GST. In fact, among all π GST mutants tested, only Cys47Ser π GST mutant failed to form a heterodimer with WT PrxVI as revealed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis in the presence or absence of DTT, suggesting that Cys47 is involved in forming the intersubunit disulfide bond between the two enzymes. The Prx VI in the heterodimer is inactive. Its activation requires reduced GSH to regenerate the active Prx VI capable of reducing hydroperoxide and phospholipid hydroperoxides, another important characteristic that sets Prx VI apart from other Prx proteins. However, it is not known whether the regenerated active form of Prx VI is a monomer or a homodimer. Unlike human Prx VI, 1-Cys D-Prx, the plant and pathogenic bacteria counterpart of human Prx V, is activated by the Grx/GSH system and exists as an active homodimer. Upon reduction of hydroperoxide, the cysteine residues in the dimer active site are oxidized to sulfenic acids. Unlike human Prx VI, this step is followed by the glutathionylation of the sulfenic acid by GSH leading to a conformational change that destabilizes and dissociates the noncovalent homodimer to monomers (see Fig. 10). The glutathionylated monomers of 1-Cys-D Prx are then reduced back by either DTT or the Grx/GSH system and lead to the regeneration of their homodimer (86).

FIG. 9. A mechanistic scheme depicting activation of the oxidized 1-Cys Prx by π GST and GSH. The activation involves the formation of a heterodimer between the GSH bound π GST and the oxidized 1-Cys Prx, which leads to the formation of a glutathionylated 1-Cys Prx intermediate and follows with the formation of a disulfide bonded heterodimer prior to its reduction by GSH.

This redox-dependent dimer-monomer switch is similar to decamer-dimer switch observed in 2-Cys Prx I that is responsible for the toggling of its peroxidase-chaperone activity (89).

It should be pointed out that recombinant Prx VI protein expressed in bacteria and native protein purified from rat lung exhibited both peroxidase and phospholipase A2 activities (61, 64), making Prx VI a bifunctional enzyme with two separate active sites (Fig. 11). Mutagenic analysis revealed that the mutation of peroxidatic cysteine, Cys⁴⁷, to serine in Prx VI abolishes the peroxidase activity but does not influence PLA2 activity (16). Likewise, the mutation

of Ser³² to alanine affects the PLA2 activity without any effect on the peroxidase activity. Note that Ser³² together with His²⁶ and Asp¹⁴⁰ forms the catalytic triad of the PLA2 active site. In addition, it has been shown that PLA2 activity and lipid binding affinity at pH 7 were markedly enhanced by Thr¹⁷⁷ phosphorylation without affecting its peroxidase activity (137). Recently, it has been reported that phospholipase A2 activity of Prx VI is required for NADPH oxidase 2 activation (15), a major source of ROS, paving the way for recognition of an important role of Prx VI, not only in antioxidant defense but also in cell signaling.

FIG. 10. Proposed peroxidase mechanism for the 1-Cys D Prx. ROOH oxidizes the S_P of 1-Cys D Prx to form an inactive sulfenic dimer. Glutathionylation of this inactive dimer induces a conformational change and causes it to dissociate into monomers. The glutathionylated monomers are reduced by the glutaredoxin/glutathione system to complete the catalytic cycle.

FIG. 11. Model of peroxiredoxin VI structure. It shows the peroxidatic Cys 47 (purple); the catalytic center for the peroxidase activity; and Ser 32 (red), His 26 (yellow), and Asp 140 (blue), the catalytic triad of the phospholipase A_2 active site. The figure is based on a figure reported by Manevich *et al.* (76). (To see this illustration in color the reader is referred to the web version of this article at www.liebertonline.com/ars).

Concluding Remarks

The complexity of the diverse activities of Prxs and their regulatory mechanisms is attributed to their redox-sensitive structural changes and binding to their protein partners, as well as their various post-translational modifications. Functional diversities enable Prxs to function as signal modulators, tumor suppressors, and apoptotic regulators as well as broad-spectrum antioxidants. Prxs react rapidly with a wide range of intracellular peroxides to form a sulfenic acid derivative with their conserved peroxidatic cysteine, S_P . However, reduction of the sulfenic intermediate differs among Prxs. They include formation of an intermolecular disulfide bond with a conserved resolving cysteine, S_R , in a typical 2-Cys Prxs, an intramolecular disulfide bond in atypical 2-Cys Prx, and formation of a disulfide bond with GSH in human 1-Cys, or with GSH, Grx, or Trx in Prxs from plant, bacteria, or worms. Reduction of these disulfide intermediates is catalyzed respectively by Trx/TrxR/NADPH, Grx/GSH/GR/NADPH, (Trx or GSH)/TGR/NADPH, or the GSH/ π GST systems. While Prxs have the capacity to remove peroxides efficiently, they also have an intrinsic vulnerability to be hyperoxidized to sulfenic or sulfonic derivatives and lose their peroxidase activity. The hyperoxidized Prxs favor the decamer/higher-order-oligomeric structures and result in the augmentation of molecular chaperone activity, which in turn protects the protein substrate from aggregation. Various reversible post-translational modifications such as hyperoxidations, phosphorylations, nitrosylations, glutathionylations, and acetylations are involved in the regulation of Prx activity. However, at this moment, their integrated control mechanism or their modification hierarchy is yet to be established.

Protein glutathionylation using GSH, the most abundant thiol in cells, as the donor molecule provides not only the reducing equivalents to peroxidase catalysis and protection of peroxidatic cysteine from irreversible hyperoxidation, it is also involved in Srx-mediated reactivation of hyperoxidized 2-Cys Prxs and in regulating the quaternary structure of Prx I. Considering that the cellular concentration of Prx I is in the range of 10–60 μ M, and the decamer/dimer dissociation constant is in the submicromolar range, the reduced Prx I in the cells exists mainly as decamers. In response to low level peroxides, Cys⁸³ of Prx I undergoes glutathionylation and leads to dimer formation. The peroxidase active dimeric Prx I in turn removes the excess peroxides more effectively; it could also bind to PTEN to protect it from oxidative inactivation and results in preventing tumorigenesis. However, when the peroxide levels are sufficiently high to induce hyperoxidation of Prx I, the hyperoxidized high molecular weight oligomers of Prx I have been shown to bind and activate MST1 kinase which in turn induces apoptosis via a p53-mediated pathway. Thus, this constitutes a mechanism for removing oxidatively damaged cells. Furthermore, the involvement of glutathionylation in the Srx-catalyzed reactivation of the inactive hyperoxidized 2-Cys Prx has been considered as a switching mechanism for maintaining a transient elevation of H_2O_2 levels for activating cell signaling cascades followed by the removal of ROS to prevent oxidatively induced cytotoxicity.

Acknowledgments

This work was supported, in the whole or in part, by the Intramural Research Program of the National Heart, Lung, and Blood Institute, National Institutes of Health. Prx research in H.Z.C. lab is supported by grant from the National Nuclear R&D Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Sciences and Technology (2010-0018772) and by CNU grant (2009-2533). S.G.R. was supported by grants from the Korean Science and Engineering Foundation (National Honor Scientist Program grant 2006-05106 and Bio R&D program grant M10642040001-07N4204-00110).

References

- Adachi T, Pimentel DR, Heibeck T, Hou X, Lee YJ, Jiang B, Ido Y, and Cohen RA. S-glutathiolation of Ras mediates redox-sensitive signaling by angiotensin II in vascular smooth muscle cells. *J Biol Chem* 279: 29857–29862, 2004.
- Alger HM and Williams DL. The disulfide redox system of *Schistosoma mansoni* and the importance of a multifunctional enzyme, thioredoxin glutathione reductase. *Mol Biochem Parasitol* 121: 129–139, 2002.
- Aslund F, Ehn B, Miranda-Vizuet A, Pueyo C, and Holmgren A. Two additional glutaredoxins exist in *Escherichia coli*: glutaredoxin 3 is a hydrogen donor for ribonucleotide reductase in a thioredoxin/glutaredoxin 1 double mutant. *Proc Natl Acad Sci U S A* 91: 9813–9817, 1994.
- Bae YS, Kang SW, Seo MS, Baines IC, Tekle E, Chock PB, and Rhee SG. Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. *J Biol Chem* 272: 217–221, 1997.

5. Barrett WC, DeGnore JP, Keng YF, Zhang ZY, Yim MB, and Chock PB. Roles of superoxide radical anion in signal transduction mediated by reversible regulation of protein-tyrosine phosphatase 1B. *J Biol Chem* 274: 34543–34546, 1999.
6. Beckman KB and Ames BN. The free radical theory of aging matures. *Physiol Rev* 78: 547–581, 1998.
7. Biteau B, Labarre J, and Toledano MB. ATP-dependent reduction of cysteine-sulphinic acid by *S. cerevisiae* sulphiredoxin. *Nature* 425: 980–984, 2003.
8. Cao J, Schulte J, Knight A, Leslie NR, Zagodzón A, Bronson R, Manevich Y, Beeson C, and Neumann CA. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. *EMBO J* 28: 1505–1517, 2009.
9. Chae HZ, Chung SJ, and Rhee SG. Thioredoxin-dependent peroxide reductase from yeast. *J Biol Chem* 269: 27670–27678, 1994.
10. Chae HZ, Kang SW, and Rhee SG. Isoforms of mammalian peroxiredoxin that reduce peroxides in presence of thioredoxin. *Methods Enzymol* 300: 219–226, 1999.
11. Chae HZ, Kim HJ, Kang SW, and Rhee SG. Characterization of three isoforms of mammalian peroxiredoxin that reduce peroxides in the presence of thioredoxin. *Diabetes Res Clin Pract* 45: 101–112, 1999.
12. Chae HZ, Robison K, Poole LB, Church G, Storz G, and Rhee SG. Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. *Proc Natl Acad Sci U S A* 91: 7017–7021, 1994.
13. Chang TS, Jeong W, Choi SY, Yu S, Kang SW, and Rhee SG. Regulation of peroxiredoxin I activity by Cdc2-mediated phosphorylation. *J Biol Chem* 277: 25370–25376, 2002.
14. Chang TS, Jeong W, Woo HA, Lee SM, Park S, and Rhee SG. Characterization of mammalian sulfiredoxin and its reactivation of hyperoxidized peroxiredoxin through reduction of cysteine sulfinic acid in the active site to cysteine. *J Biol Chem* 279: 50994–51001, 2004.
15. Chatterjee S, Feinstein SI, Dodia C, Sorokina E, Lien YC, Nguyen S, Debolt K, Speicher D, and Fisher AB. Peroxiredoxin 6 phosphorylation and subsequent phospholipase A2 activity are required for agonist-mediated activation of NADPH oxidase in mouse pulmonary microvascular endothelium and alveolar macrophages. *J Biol Chem* 286: 11696–11706, 2011.
16. Chen JW, Dodia C, Feinstein SI, Jain MK, and Fisher AB. 1-Cys peroxiredoxin, a bifunctional enzyme with glutathione peroxidase and phospholipase A2 activities. *J Biol Chem* 275: 28421–28427, 2000.
17. Chen YR, Chen CL, Pfeiffer DR, and Zweier JL. Mitochondrial complex II in the post-ischemic heart: oxidative injury and the role of protein S-glutathionylation. *J Biol Chem* 282: 32640–32654, 2007.
18. Cho CS, Lee S, Lee GT, Woo HA, Choi EJ, and Rhee SG. Irreversible inactivation of glutathione peroxidase 1 and reversible inactivation of peroxiredoxin II by H₂O₂ in red blood cells. *Antioxid Redox Signal* 12: 1235–1246, 2010.
19. Chock PB, Rhee SG, and Stadtman ER. Interconvertible enzyme cascades in cellular regulation. *Annu Rev Biochem* 49: 813–843, 1980.
20. Chock PB and Stadtman ER. Cyclic cascades in cellular regulation. In: *Principles of Medical Biology*. Edited by Bittar EE, Bittar N. Greenwich, CT: JAI Press Inc., 1996. pp. 201–220.
21. Choi HJ, Kang SW, Yang CH, Rhee SG, and Ryu SE. Crystal structure of a novel human peroxidase enzyme at 2.0 Å resolution. *Nat Struct Biol* 5: 400–406, 1998.
22. Choi YB, Tenneti L, Le DA, Ortiz J, Bai G, Chen HS, and Lipton SA. Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. *Nat Neurosci* 3: 15–21, 2000.
23. Chrestensen CA, Starke DW, and Mieyal JJ. Acute cadmium exposure inactivates thioltransferase (Glutaredoxin), inhibits intracellular reduction of protein-glutathionyl-mixed disulfides, and initiates apoptosis. *J Biol Chem* 275: 26556–26565, 2000.
24. Chung KK, Thomas B, Li X, Pletnikova O, Troncoso JC, Marsh L, Dawson VL, and Dawson TM. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. *Science* 304: 1328–1331, 2004.
25. Claiborne A, Miller H, Parsonage D, and Ross RP. Protein-sulfenic acid stabilization and function in enzyme catalysis and gene regulation. *FASEB J* 7: 1483–1490, 1993.
26. Claiborne A, Yeh JI, Mallett TC, Luba J, Crane EJ, 3rd, Charrier V, and Parsonage D. Protein-sulfenic acids: diverse roles for an unlikely player in enzyme catalysis and redox regulation. *Biochemistry* 38: 15407–15416, 1999.
27. Dalle-Donne I, Rossi R, Colombo G, Giustarini D, and Milzani A. Protein S-glutathionylation: a regulatory device from bacteria to humans. *Trends Biochem Sci* 34: 85–96, 2009.
28. Dietz KJ. Plant peroxiredoxins. *Annu Rev Plant Biol* 54: 93–107, 2003.
29. Dietz KJ. Peroxiredoxins in plants and cyanobacteria. *Antioxid Redox Signal* 15: 1129–1159, 2011.
30. Echalié A, Trivelli X, Corbier C, Rouhier N, Walker O, Tsan P, Jacquot JP, Aubry A, Krimm I, and Lancelin JM. Crystal structure and solution NMR dynamics of a D (type II) peroxiredoxin glutaredoxin and thioredoxin dependent: a new insight into the peroxiredoxin oligomerism. *Biochemistry* 44: 1755–1767, 2005.
31. Evrard C, Capron A, Marchand C, Clippe A, Wattiez R, Soumillion P, Knoops B, and Declercq JP. Crystal structure of a dimeric oxidized form of human peroxiredoxin 5. *J Mol Biol* 337: 1079–1090, 2004.
32. Fang J, Nakamura T, Cho DH, Gu Z, and Lipton SA. S-nitrosylation of peroxiredoxin 2 promotes oxidative stress-induced neuronal cell death in Parkinson's disease. *Proc Natl Acad Sci U S A* 104: 18742–18747, 2007.
33. Findlay VJ, Townsend DM, Morris TE, Fraser JP, He L, and Tew KD. A novel role for human sulfiredoxin in the reversal of glutathionylation. *Cancer Res* 66: 6800–6806, 2006.
34. Fisher AB. Peroxiredoxin 6: a bifunctional enzyme with glutathione peroxidase and phospholipase a(2) activities. *Antioxid Redox Signal* 15: 831–844, 2011.
35. Fisher AB, Dodia C, Manevich Y, Chen JW, and Feinstein SI. Phospholipid hydroperoxides are substrates for non-selenium glutathione peroxidase. *J Biol Chem* 274: 21326–21334, 1999.
36. Flohe L, Toppo S, Cozza G, and Ursini F. A comparison of thiol peroxidase mechanisms. *Antioxid Redox Signal* 15: 763–780, 2011.
37. Fratelli M, Demol H, Puype M, Casagrande S, Eberini I, Salmons M, Bonetto V, Mengozzi M, Duffieux F, Miclet E, Bachi A, Vandekerckhove J, Gianazza E, and Ghezzi P. Identification by redox proteomics of glutathionylated proteins in oxidatively stressed human T lymphocytes. *Proc Natl Acad Sci U S A* 99: 3505–3510, 2002.

38. Fratelli M, Demol H, Puype M, Casagrande S, Villa P, Eberini I, Vandekerckhove J, Gianazza E, and Ghezzi P. Identification of proteins undergoing glutathionylation in oxidatively stressed hepatocytes and hepatoma cells. *Proteomics* 3: 1154–1161, 2003.
39. Gilbert HF. Thiol/disulfide exchange equilibria and disulfide bond stability. *Methods Enzymol* 251: 8–28, 1995.
40. Go YM and Jones DP. Redox control systems in the nucleus: mechanisms and functions. *Antioxid Redox Signal* 13: 489–509, 2010.
41. Graves JA, Metukuri M, Scott D, Rothermund K, and Prochownik EV. Regulation of reactive oxygen species homeostasis by peroxiredoxins and c-Myc. *J Biol Chem* 284: 6520–6529, 2009.
42. Greetham D and Grant CM. Antioxidant activity of the yeast mitochondrial one-Cys peroxiredoxin is dependent on thioredoxin reductase and glutathione in vivo. *Mol Cell Biol* 29: 3229–3240, 2009.
43. Hall A, Karplus PA, and Poole LB. Typical 2-Cys peroxiredoxins—structures, mechanisms and functions. *FEBS J* 276: 2469–2477, 2009.
44. Hall A, Nelson K, Poole LB, and Karplus PA. Structure-based insights into the catalytic power and conformational dexterity of peroxiredoxins. *Antioxid Redox Signal* 15: 795–815, 2011.
45. Hall A, Parsonage D, Poole LB, and Karplus PA. Structural evidence that peroxiredoxin catalytic power is based on transition-state stabilization. *J Mol Biol* 402: 194–209, 2010.
46. Harris JR. Release of a macromolecular protein component from human erythrocyte ghosts. *Biochim Biophys Acta* 150: 534–537, 1968.
47. Hirotsu S, Abe Y, Okada K, Nagahara N, Hori H, Nishino T, and Hakoshima T. Crystal structure of a multifunctional 2-Cys peroxiredoxin heme-binding protein 23 kDa/proliferation-associated gene product. *Proc Natl Acad Sci U S A* 96: 12333–12338, 1999.
48. Hofmann B, Hecht HJ, and Flohe L. Peroxiredoxins. *Biol Chem* 383: 347–364, 2002.
49. Holmgren A. Thioredoxin and glutaredoxin systems. *J Biol Chem* 264: 13963–13966, 1989.
50. Hu X, Weng Z, Chu CT, Zhang L, Cao G, Gao Y, Signore A, Zhu J, Hastings T, Greenamyre JT, and Chen J. Peroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade. *J Neurosci* 31: 247–261, 2011.
51. Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. *Cell* 80: 225–236, 1995.
52. Hwang C, Sinskey AJ, and Lodish HF. Oxidized redox state of glutathione in the endoplasmic reticulum. *Science* 257: 1496–1502, 1992.
53. Jacobson FS, Morgan RW, Christman MF, and Ames BN. An alkyl hydroperoxide reductase from *Salmonella typhimurium* involved in the defense of DNA against oxidative damage. Purification and properties. *J Biol Chem* 264: 1488–1496, 1989.
54. Jang HH, Kim SY, Park SK, Jeon HS, Lee YM, Jung JH, Lee SY, Chae HB, Jung YJ, Lee KO, Lim CO, Chung WS, Bahk JD, Yun DJ, and Cho MJ. Phosphorylation and concomitant structural changes in human 2-Cys peroxiredoxin isotype I differentially regulate its peroxidase and molecular chaperone functions. *FEBS Lett* 580: 351–355, 2006.
55. Jang HH, Lee KO, Chi YH, Jung BG, Park SK, Park JH, Lee JR, Lee SS, Moon JC, Yun JW, Choi YO, Kim WY, Kang JS, Cheong GW, Yun DJ, Rhee SG, Cho MJ, and Lee SY. Two enzymes in one; two yeast peroxiredoxins display oxidative stress-dependent switching from a peroxidase to a molecular chaperone function. *Cell* 117: 625–635, 2004.
56. Jin DY, Chae HZ, Rhee SG, and Jeang KT. Regulatory role for a novel human thioredoxin peroxidase in NF-kappaB activation. *J Biol Chem* 272: 30952–30961, 1997.
57. Jonsson TJ, Murray MS, Johnson LC, and Lowther WT. Reduction of cysteine sulfinic acid in peroxiredoxin by sulfiredoxin proceeds directly through a sulfinic phosphoryl ester intermediate. *J Biol Chem* 283: 23846–23851, 2008.
58. Jonsson TJ, Tsang AW, Lowther WT, and Furdul CM. Identification of intact protein thiosulfinate intermediate in the reduction of cysteine sulfinic acid in peroxiredoxin by human sulfiredoxin. *J Biol Chem* 283: 22890–22894, 2008.
59. Jung CH and Thomas JA. S-glutathiolated hepatocyte proteins and insulin disulfides as substrates for reduction by glutaredoxin, thioredoxin, protein disulfide isomerase, and glutathione. *Arch Biochem Biophys* 335: 61–72, 1996.
60. Kanda M, Ihara Y, Murata H, Urata Y, Kono T, Yodoi J, Seto S, Yano K, and Kondo T. Glutaredoxin modulates platelet-derived growth factor-dependent cell signaling by regulating the redox status of low molecular weight protein-tyrosine phosphatase. *J Biol Chem* 281: 28518–28528, 2006.
61. Kang SW, Baines IC, and Rhee SG. Characterization of a mammalian peroxiredoxin that contains one conserved cysteine. *J Biol Chem* 273: 6303–6311, 1998.
62. Kim IH, Kim K, and Rhee SG. Induction of an antioxidant protein of *Saccharomyces cerevisiae* by O₂, Fe³⁺, or 2-mercaptoethanol. *Proc Natl Acad Sci U S A* 86: 6018–6022, 1989.
63. Kim K, Kim IH, Lee KY, Rhee SG, and Stadtman ER. The isolation and purification of a specific "protector" protein which inhibits enzyme inactivation by a thiol/Fe(III)/O₂ mixed-function oxidation system. *J Biol Chem* 263: 4704–4711, 1988.
64. Kim TS, Sundaresh CS, Feinstein SI, Dodia C, Skach WR, Jain MK, Nagase T, Seki N, Ishikawa K, Nomura N, and Fisher AB. Identification of a human cDNA clone for lysosomal type Ca²⁺-independent phospholipase A₂ and properties of the expressed protein. *J Biol Chem* 272: 2542–2550, 1997.
65. Knoops B, Goemaere J, Van der Eecken V, and Declercq JP. Peroxiredoxin 5: structure, mechanism, and function of the Mammalian atypical 2-cys peroxiredoxin. *Antioxid Redox Signal* 15: 817–829, 2011.
66. Kosower NS, Kosower EM, Wertheim B, and Correa WS. Diamide, a new reagent for the intracellular oxidation of glutathione to the disulfide. *Biochem Biophys Res Commun* 37: 593–596, 1969.
67. Lee J, Spector D, Godon C, Labarre J, and Toledano MB. A new antioxidant with alkyl hydroperoxide defense properties in yeast. *J Biol Chem* 274: 4537–4544, 1999.
68. Lee KO, Lee JR, Yoo JY, Jang HH, Moon JC, Jung BG, Chi YH, Park SK, Lee SS, Lim CO, Yun DJ, Cho MJ, and Lee SY. GSH-dependent peroxidase activity of the rice (*Oryza sativa*) glutaredoxin, a thioltransferase. *Biochem Biophys Res Commun* 296: 1152–1156, 2002.
69. Lee KW, Lee DJ, Lee JY, Kang DH, Kwon J, and Kang SW. Peroxiredoxin II restrains DNA damage-induced death in

- cancer cells by positively regulating JNK-dependent DNA repair. *J Biol Chem* 286: 8394–8404, 2011.
70. Lee TH, Kim SU, Yu SL, Kim SH, Park DS, Moon HB, Dho SH, Kwon KS, Kwon HJ, Han YH, Jeong S, Kang SW, Shin HS, Lee KK, Rhee SG, and Yu DY. Peroxiredoxin II is essential for sustaining life span of erythrocytes in mice. *Blood* 101: 5033–5038, 2003.
71. Lillig CH, Berndt C, and Holmgren A. Glutaredoxin systems. *Biochim Biophys Acta* 1780: 1304–1317, 2008.
72. Lim JC, Choi HI, Park YS, Nam HW, Woo HA, Kwon KS, Kim YS, Rhee SG, Kim K, and Chae HZ. Irreversible oxidation of the active-site cysteine of peroxiredoxin to cysteine sulfonic acid for enhanced molecular chaperone activity. *J Biol Chem* 283: 28873–28880, 2008.
73. Lim SK, Kim JC, Moon CJ, Kim GY, Han HJ, and Park SH. Formaldehyde induces apoptosis through decreased Prx 2 via p38 MAPK in lung epithelial cells. *Toxicology* 271: 100–106, 2010.
74. Lowther WT and Haynes AC. Reduction of cysteine sulfenic acid in eukaryotic, typical 2-cys peroxiredoxins by sulfiredoxin. *Antioxid Redox Signal* 15: 99–109, 2011.
75. Manevich Y, Feinstein SI, and Fisher AB. Activation of the antioxidant enzyme 1-CYS peroxiredoxin requires glutathionylation mediated by heterodimerization with pi GST. *Proc Natl Acad Sci U S A* 101: 3780–3785, 2004.
76. Manevich Y, Reddy KS, Shuvaeva T, Feinstein SI, and Fisher AB. Structure and phospholipase function of peroxiredoxin 6: identification of the catalytic triad and its role in phospholipid substrate binding. *J Lipid Res* 48: 2306–2318, 2007.
77. Marshall HE, Hess DT, and Stamler JS. S-nitrosylation: physiological regulation of NF-kappaB. *Proc Natl Acad Sci U S A* 101: 8841–8842, 2004.
78. Matsumura T, Okamoto K, Iwahara S, Hori H, Takahashi Y, Nishino T, and Abe Y. Dimer-oligomer interconversion of wild-type and mutant rat 2-Cys peroxiredoxin: disulfide formation at dimer-dimer interfaces is not essential for decamerization. *J Biol Chem* 283: 284–293, 2008.
79. Mieyal JJ, Gallogly MM, Qanungo S, Sabens EA, and Shelton MD. Molecular mechanisms and clinical implications of reversible protein S-glutathionylation. *Antioxid Redox Signal* 10: 1941–1988, 2008.
80. Mieyal JJ, Srinivaan U, Starke DW, Gravina SA, and Mieyal PA. Glutathionyl specificity of the thiotransferases: mechanistic and physiological implications. In: *Biothiols in Health and Disease*. Edited by L. Packer and E. Cadenas. New York: Marcel Dekker Inc., 1995. pp. 305–372.
81. Monteiro G, Horta BB, Pimenta DC, Augusto O, and Netto LE. Reduction of 1-Cys peroxiredoxins by ascorbate changes the thiol-specific antioxidant paradigm, revealing another function of vitamin C. *Proc Natl Acad Sci U S A* 104: 4886–4891, 2007.
82. Moon JC, Hah YS, Kim WY, Jung BG, Jang HH, Lee JR, Kim SY, Lee YM, Jeon MG, Kim CW, Cho MJ, and Lee SY. Oxidative stress-dependent structural and functional switching of a human 2-Cys peroxiredoxin isotype II that enhances HeLa cell resistance to H₂O₂-induced cell death. *J Biol Chem* 280: 28775–28784, 2005.
83. Morinaka A, Funato Y, Uesugi K, and Miki H. Oligomeric peroxiredoxin-I is an essential intermediate for p53 to activate MST1 kinase and apoptosis. *Oncogene* 30: 4208–4218, 2011.
84. Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, Abraham JL, Bronson RT, Fujiwara Y, Orkin SH, and Van Etten RA. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. *Nature* 424: 561–565, 2003.
85. Nogoceke E, Gommel DU, Kiess M, Kalisz HM, and Flohe L. A unique cascade of oxidoreductases catalyses trypanothione-mediated peroxide metabolism in *Crithidia fasciculata*. *Biol Chem* 378: 827–836, 1997.
86. Noguera-Mazon V, Lemoine J, Walker O, Rouhier N, Salvador A, Jacquot JP, Lancelin JM, and Krimm I. Glutathionylation induces the dissociation of 1-Cys D- peroxiredoxin non-covalent homodimer. *J Biol Chem* 281: 31736–31742, 2006.
87. Ogusucu R, Rettori D, Munhoz DC, Netto LE, and Augusto O. Reactions of yeast thioredoxin peroxidases I and II with hydrogen peroxide and peroxyxynitrite: rate constants by competitive kinetics. *Free Radic Biol Med* 42: 326–334, 2007.
88. Park JW, Mieyal JJ, Rhee SG, and Chock PB. Deglutathionylation of 2-Cys peroxiredoxin is specifically catalyzed by sulfiredoxin. *J Biol Chem* 284: 23364–23374, 2009.
89. Park JW, Piszczek G, Rhee SG, and Chock PB. Glutathionylation of peroxiredoxin I induces decamer to dimers dissociation with concomitant loss of chaperone activity. *Biochemistry* 50: 3204–3210, 2011.
90. Parmigiani RB, Xu WS, Venta-Perez G, Erdjument-Bromage H, Yaneva M, Tempst P, and Marks PA. HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. *Proc Natl Acad Sci U S A* 105: 9633–9638, 2008.
91. Parsonage D, Youngblood DS, Sarma GN, Wood ZA, Karplus PA, and Poole LB. Analysis of the link between enzymatic activity and oligomeric state in AhpC, a bacterial peroxiredoxin. *Biochemistry* 44: 10583–10592, 2005.
92. Pauwels F, Vergauwen B, Vanrobaeys F, Devreese B, and Van Beeumen JJ. Purification and characterization of a chimeric enzyme from *Haemophilus influenzae* Rd that exhibits glutathione-dependent peroxidase activity. *J Biol Chem* 278: 16658–16666, 2003.
93. Pedrajas JR, Miranda-Vizuete A, Javanmardy N, Gustafsson JA, and Spyrou G. Mitochondria of *Saccharomyces cerevisiae* contain one-conserved cysteine type peroxiredoxin with thioredoxin peroxidase activity. *J Biol Chem* 275: 16296–16301, 2000.
94. Pedrajas JR, Padilla CA, McDonagh B, and Barcena JA. Glutaredoxin participates in the reduction of peroxides by the mitochondrial 1-CYS peroxiredoxin in *Saccharomyces cerevisiae*. *Antioxid Redox Signal* 13: 249–258, 2010.
95. Peshenko IV and Shichi H. Oxidation of active center cysteine of bovine 1-Cys peroxiredoxin to the cysteine sulfenic acid form by peroxide and peroxyxynitrite. *Free Radic Biol Med* 31: 292–303, 2001.
96. Peshenko IV, Singh AK, and Shichi H. Bovine eye 1-Cys peroxiredoxin: expression in *E. coli* and antioxidant properties. *J Ocul Pharmacol Ther* 17: 93–99, 2001.
97. Qu D, Rashidian J, Mount MP, Aleyasin H, Parsanejad M, Lira A, Haque E, Zhang Y, Callaghan S, Daigle M, Rousseaux MW, Slack RS, Albert PR, Vincent I, Woulfe JM, and Park DS. Role of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson's disease. *Neuron* 55: 37–52, 2007.
98. Rabilloud T, Heller M, Gasnier F, Luche S, Rey C, Aebbersold R, Benahmed M, Louisot P, and Lunardi J. Proteomics analysis of cellular response to oxidative stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site. *J Biol Chem* 277: 19396–19401, 2002.

99. Ralat LA, Manevich Y, Fisher AB, and Colman RF. Direct evidence for the formation of a complex between 1-cysteine peroxiredoxin and glutathione S-transferase pi with activity changes in both enzymes. *Biochemistry* 45: 360–372, 2006.
100. Ralat LA, Misquitta SA, Manevich Y, Fisher AB, and Colman RF. Characterization of the complex of glutathione S-transferase pi and 1-cysteine peroxiredoxin. *Arch Biochem Biophys* 474: 109–118, 2008.
101. Rhee SG. Redox signaling: hydrogen peroxide as intracellular messenger. *Exp Mol Med* 31: 53–59, 1999.
102. Rhee SG. Cell signaling. H₂O₂, a necessary evil for cell signaling. *Science* 312: 1882–1883, 2006.
103. Rhee SG, Chae HZ, and Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. *Free Radic Biol Med* 38: 1543–1552, 2005.
104. Rhee SG, Kang SW, Chang TS, Jeong W, and Kim K. Peroxiredoxin, a novel family of peroxidases. *IUBMB Life* 52: 35–41, 2001.
105. Rhee SG and Woo HA. Multiple functions of peroxiredoxins: peroxidases, sensors and regulators of the intracellular messenger H₂O₂, and protein chaperones. *Antioxid Redox Signal* 15: 781–794, 2011.
106. Rhee SG, Yang KS, Kang SW, Woo HA, and Chang TS. Controlled elimination of intracellular H₂O₂: regulation of peroxiredoxin, catalase, and glutathione peroxidase via post-translational modification. *Antioxid Redox Signal* 7: 619–626, 2005.
107. Rodriguez-Pascual F, Redondo-Horcajo M, Magan-Marchal N, Lagares D, Martinez-Ruiz A, Kleinert H, and Lamas S. Glyceraldehyde-3-phosphate dehydrogenase regulates endothelin-1 expression by a novel, redox-sensitive mechanism involving mRNA stability. *Mol Cell Biol* 28: 7139–7155, 2008.
108. Rouhier N. Plant glutaredoxins: pivotal players in redox biology and iron-sulphur centre assembly. *New Phytol* 186: 365–372, 2010.
109. Rouhier N, Gelhaye E, and Jacquot JP. Glutaredoxin-dependent peroxiredoxin from poplar: protein-protein interaction and catalytic mechanism. *J Biol Chem* 277: 13609–13614, 2002.
110. Rouhier N, Gelhaye E, Sautiere PE, Brun A, Laurent P, Tagu D, Gerard J, de Fay E, Meyer Y, and Jacquot JP. Isolation and characterization of a new peroxiredoxin from poplar sieve tubes that uses either glutaredoxin or thioredoxin as a proton donor. *Plant Physiol* 127: 1299–1309, 2001.
111. Roussel X, Bechade G, Kriznik A, Van Dorsselaer A, Sanglier-Cianferani S, Branlant G, and Rahuel-Clermont S. Evidence for the formation of a covalent thiosulfinate intermediate with peroxiredoxin in the catalytic mechanism of sulfiredoxin. *J Biol Chem* 283: 22371–22382, 2008.
112. Roussel X, Kriznik A, Richard C, Rahuel-Clermont S, and Branlant G. Catalytic mechanism of Sulfiredoxin from *Saccharomyces cerevisiae* passes through an oxidized disulfide sulfiredoxin intermediate that is reduced by thioredoxin. *J Biol Chem* 284: 33048–33055, 2009.
113. Sayed AA and Williams DL. Biochemical characterization of 2-Cys peroxiredoxins from *Schistosoma mansoni*. *J Biol Chem* 279: 26159–26166, 2004.
114. Schafer FQ and Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. *Free Radic Biol Med* 30: 1191–1212, 2001.
115. Schroder E, Littlechild JA, Lebedev AA, Errington N, Vagin AA, and Isupov MN. Crystal structure of decameric 2-Cys peroxiredoxin from human erythrocytes at 1.7 Å resolution. *Structure* 8: 605–615, 2000.
116. Seaver LC and Inlay JA. Alkyl hydroperoxide reductase is the primary scavenger of endogenous hydrogen peroxide in *Escherichia coli*. *J Bacteriol* 183: 7173–7181, 2001.
117. Seo JH, Lim JC, Lee DY, Kim KS, Piszczek G, Nam HW, Kim YS, Ahn T, Yun CH, Kim K, Chock PB, and Chae HZ. Novel protective mechanism against irreversible hyperoxidation of peroxiredoxin: Nalpha-terminal acetylation of human peroxiredoxin II. *J Biol Chem* 284: 13455–13465, 2009.
118. Seo MS, Kang SW, Kim K, Baines IC, Lee TH, and Rhee SG. Identification of a new type of mammalian peroxiredoxin that forms an intramolecular disulfide as a reaction intermediate. *J Biol Chem* 275: 20346–20354, 2000.
119. Shelton MD, Chock PB, and Mieyal JJ. Glutaredoxin: role in reversible protein s-glutathionylation and regulation of redox signal transduction and protein translocation. *Antioxid Redox Signal* 7: 348–366, 2005.
120. Shichi H and Demar JC. Non-selenium glutathione peroxidase without glutathione S-transferase activity from bovine ciliary body. *Exp Eye Res* 50: 513–520, 1990.
121. Shiota M, Yokomizo A, Kashiwagi E, Takeuchi A, Fujimoto N, Uchiumi T, and Naito S. Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells. *Free Radic Biol Med* 51: 78–87, 2011.
122. Singh AK and Shichi H. A novel glutathione peroxidase in bovine eye. Sequence analysis, mRNA level, and translation. *J Biol Chem* 273: 26171–26178, 1998.
123. Stadtman ER and Berlett BS. Reactive oxygen-mediated protein oxidation in aging and disease. *Chem Res Toxicol* 10: 485–494, 1997.
124. Stadtman ER and Chock PB. Advantages of enzyme cascades in the regulation of key metabolic processes. In: *The Neurosciences Fourth Study Program*. Edited by FO Schmitt and FG Worden. Cambridge, MA: MIT Press, 1979. pp. 801–817.
125. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, and Finkel T. Requirement for generation of H₂O₂ for platelet-derived growth factor signal transduction. *Science* 270: 296–299, 1995.
126. Tavender TJ, Sheppard AM, and Bulleid NJ. Peroxiredoxin IV is an endoplasmic reticulum-localized enzyme forming oligomeric complexes in human cells. *Biochem J* 411: 191–199, 2008.
127. Thannickal VJ and Fanburg BL. Reactive oxygen species in cell signaling. *Am J Physiol Lung Cell Mol Physiol* 279: L1005–L1028, 2000.
128. Wang G, Moniri NH, Ozawa K, Stamler JS, and Daaka Y. Nitric oxide regulates endocytosis by S-nitrosylation of dynamin. *Proc Natl Acad Sci U S A* 103: 1295–1300, 2006.
129. Wang J, Boja ES, Tan W, Tekle E, Fales HM, English S, Mieyal JJ, and Chock PB. Reversible glutathionylation regulates actin polymerization in A431 cells. *J Biol Chem* 276: 47763–47766, 2001.
130. Wang J, Tekle E, Oubrahim H, Mieyal JJ, Stadtman ER, and Chock PB. Stable and controllable RNA interference: Investigating the physiological function of glutathionylated actin. *Proc Natl Acad Sci U S A* 100: 5103–5106, 2003.

131. Woo HA, Chae HZ, Hwang SC, Yang KS, Kang SW, Kim K, and Rhee SG. Reversing the inactivation of peroxiredoxins caused by cysteine sulfinic acid formation. *Science* 300: 653–656, 2003.
132. Woo HA, Jeong W, Chang TS, Park KJ, Park SJ, Yang JS, and Rhee SG. Reduction of cysteine sulfinic acid by sulfiredoxin is specific to 2-cys peroxiredoxins. *J Biol Chem* 280: 3125–3128, 2005.
133. Woo HA, Yim SH, Shin DH, Kang D, Yu DY, and Rhee SG. Inactivation of peroxiredoxin I by phosphorylation allows localized H(2)O(2) accumulation for cell signaling. *Cell* 140: 517–528, 2010.
134. Wood ZA, Poole LB, Hantgan RR, and Karplus PA. Dimers to doughnuts: redox-sensitive oligomerization of 2-cysteine peroxiredoxins. *Biochemistry* 41: 5493–5504, 2002.
135. Wood ZA, Poole LB, and Karplus PA. Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. *Science* 300: 650–653, 2003.
136. Wood ZA, Schroder E, Robin Harris J, and Poole LB. Structure, mechanism and regulation of peroxiredoxins. *Trends Biochem Sci* 28: 32–40, 2003.
137. Wu Y, Feinstein SI, Manevich Y, Chowdhury I, Pak JH, Kazi A, Dodia C, Speicher DW, and Fisher AB. Mitogen-activated protein kinase-mediated phosphorylation of peroxiredoxin 6 regulates its phospholipase A(2) activity. *Biochem J* 419: 669–679, 2009.
138. Yang KS, Kang SW, Woo HA, Hwang SC, Chae HZ, Kim K, and Rhee SG. Inactivation of human peroxiredoxin I during catalysis as the result of the oxidation of the catalytic site cysteine to cysteine-sulfinic acid. *J Biol Chem* 277: 38029–38036, 2002.
139. Yao D, Gu Z, Nakamura T, Shi ZQ, Ma Y, Gaston B, Palmer LA, Rockenstein EM, Zhang Z, Masliah E, Uehara T, and Lipton SA. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. *Proc Natl Acad Sci U S A* 101: 10810–10814, 2004.
140. Yi CH, Pan H, Seebacher J, Jang IH, Hyberts SG, Heffron GJ, Vander Heiden MG, Yang R, Li F, Locasale JW, Sharfi H, Zhai B, Rodriguez-Mias R, Luithardt H, Cantley LC, Daley GQ, Asara JM, Gygi SP, Wagner G, Liu CF, and Yuan J. Metabolic regulation of protein N-alpha-acetylation by Bcl-xL promotes cell survival. *Cell* 146: 607–620, 2011.
141. Yoshida T, Inoue R, Morii T, Takahashi N, Yamamoto S, Hara Y, Tominaga M, Shimizu S, Sato Y, and Mori Y. Nitric oxide activates TRP channels by cysteine S-nitrosylation. *Nat Chem Biol* 2: 596–607, 2006.
142. Zykova TA, Zhu F, Vakorina TI, Zhang J, Higgins LA, Urusova DV, Bode AM, and Dong Z. T-LAK cell-originated protein kinase (TOPK) phosphorylation of Prx1 at Ser-32 prevents UVB-induced apoptosis in RPMI7951 melanoma cells through the regulation of Prx1 peroxidase activity. *J Biol Chem* 285: 29138–29146, 2010.

Address correspondence to:

Dr. P. Boon Chock

Laboratory of Biochemistry

National Heart, Lung, and Blood Institute

National Institutes of Health

Building 50, Room 2134, MSC-8012

Bethesda, MD 20892-8012

E-mail: bchock@nih.gov

Date of first submission to ARS Central, August 30, 2011; date of final revised submission, November 21, 2011; date of acceptance, November 23, 2011.

Abbreviations used

AhpC = 22-kDa catalytic subunit of alkyl hydroperoxide reductase
 BioGEE = biotinylated glutathione ethyl ester
 Cdk1 = cyclin B-dependent kinase 1
 Cdk = cyclin-dependent kinase
 Cp = peroxidatic cysteine
 C_R = resolving cysteine
 DTT = dithiothreitol
 GAPDH = glyceraldehyde-3-phosphate dehydrogenase
 GR = glutathione reductase
 Grx = glutaredoxin
 GSH = glutathione
 MST1 = mammalian sterile 20 like 1 kinase
 NADPH = nicotinamide adenine dinucleotide phosphate
 PABA/NO = a diazeniumdiolate of structure
 Me₂ NN(O) = NOAr (Ar is a 5-substituted-2,4-dinitrophenyl ring, 5-substituent is N-methyl-p-aminobenzoic acid)
 πGST = π isozyme of glutathione S-transferase
 Prx = peroxiredoxin
 PTEN = phosphatase and tensin homolog
 ROOH = organic peroxide
 ROS = reactive oxygen species
 S128W/NTD = (S128W) mutant of N-terminal domain of AhpF include residues 1–202
 S_p = sulfur atom of peroxidatic cysteine residue or peroxidase cysteine
 S_R = sulfur atom of resolving cysteine residue or resolving cysteine
 Srx = sulfiredoxin
 TGR = Trx-glutathione reductase
 Trx = thioredoxin
 TrxR = thioredoxin reductase
 WT = wild type